{
    "root": "308b35ea-73d1-105d-e063-6294a90a2b75",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Venlafaxine Hydrochloride",
    "value": "20250317",
    "ingredients": [
        {
            "name": "ETHYLCELLULOSE (20 MPA.S)",
            "code": "BJG0S321QY"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "VENLAFAXINE HYDROCHLORIDE",
            "code": "7D7RX5A8MO"
        }
    ],
    "indications": "Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:\n                  \n                  \n                     Major Depressive Disorder (MDD)\n  \n   [see\n   \n    Clinical Studies (14.1)]\n  \n   \n                     \n                     Generalized Anxiety Disorder (GAD)\n  \n   [see\n   \n    Clinical Studies (14.2)]\n  \n   \n                     \n                     Social Anxiety Disorder (SAD)\n  \n   [see\n   \n    Clinical Studies (14.3)]\n  \n   \n                     \n                      Panic Disorder (PD)\n  \n   [see\n   \n    Clinical Studies (14.4)]",
    "contraindications": "Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day GAD ( 2.3 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day SAD ( 2.4 ) 75 mg/day 75 mg/day 75 mg/day PD ( 2.5 ) 37.5 mg/day 75 mg/day 225 mg/day Take once daily with food. Capsules should be taken whole; do not divide, crush, chew, or dissolve ( 2.1 ). When discontinuing treatment, reduce the dose gradually ( 2.10 , 5.7 ). Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment ( 2.9 ). Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50% ( 2.8 ).",
    "warningsAndPrecautions": "Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5 mg are white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘3’) of opaque grey color cap and opaque peach color body imprinted with “E” on cap and “73” on the body with edible black ink.\n                  \n                  NDC: 70518-2532-00\n                  NDC: 70518-2532-01\n                  NDC: 70518-2532-02\n                  NDC: 70518-2532-03\n                  NDC: 70518-2532-04\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Venlafaxine hydrochloride extended-release capsules are contraindicated in patients:\n                  \n                  \n                     with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation\n  \n   [see\n   \n    Adverse Reactions (6.2)]\n  \n   .\n \n  \n                  \n                  \n                  \n                      taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome\n  \n   [see\n   \n    Dosage and Administration (2.11),\n   \n    Warnings and Precautions (5.2), and\n   \n    Drug Interactions (7.1)]\n  \n   ."
}